Incidence and risk factors of kidney impairment on patients with COVID-19: A meta-analysis of 10180 patients.

BACKGROUND: The novel coronavirus is pandemic around the world. Several researchers have given the evidence of impacts of COVID-19 on the respiratory, cardiovascular and gastrointestinal system. Studies still have debated on kidney injury of COVID-19 patients. The purpose of the meta-analysis was to evaluate the association of kidney impairment with the development of COVID-19.
METHODS: The PubMed, Embase and MedRxiv databases were searched until May 1, 2020. We extracted data from eligible studies to summarize the clinical manifestations and laboratory indexes of kidney injury on COVID-19 infection patients and further compared the prevalence of acute kidney injury (AKI) and the mean differences of three biomarkers between in ICU/severe and non-ICU/non-severe cases. Heterogeneity was evaluated using the I2 method.
RESULTS: In the sum of 24 studies with 10180 patients were included in this analysis. The pooled prevalence of AKI, increased serum creatinine (Scr), increased blood urea nitrogen (BUN), increased D-dimer, proteinuria and hematuria in patients with COVID-19 were 16.2%, 8.3%, 6.2%, 49.8%, 50.1% and 30.3% respectively. Moreover, the means of Scr, BUN and D-dimer were shown 6.4-folds, 1.8-folds and 0.67-folds, respectively, higher in ICU/severe cases than in corresponding non-ICU/non-severe patients. The prevalence of AKI was about 30 folds higher in ICU/severe patients compared with the non-ICU/non-severe cases.
CONCLUSIONS: Overall, we assessed the incidences of the clinic and laboratory features of kidney injury in COVID-19 patients. And kidney dysfunction may be a risk factor for COVID-19 patients developing into the severe condition. In reverse, COVID-19 can also cause damage to the kidney.

Introduction

In December 2019, a group of pneumonia cases caused by an unknown virus was first reported in Wuhan, Hubei province, China [1, 2]. Those cases have similar symptoms of virus infection, including fever, fatigue, and dry cough as well as myalgia, dyspnea [1, 2]. WHO has officially named this novel coronavirus as severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) after the pathogen was isolated and identificated [3, 4]. Nowadays, this novel coronavirus is causing COVID-19 epidemic on the international scale due to its highly transmissive and contagiousness, compared with other coronavirus infection diseases including Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) [5]. As of October 15, 2020, a total of 38129806 confirmed cases involved in 185 countries and regions, and the numbers continue to rise. And SARS-CoV-2 mainly causes a series of the clinical characteristics in the respiratory system, such as asymptomatic infection, mild upper respiratory tract illness, severe acute respiratory distress syndrome, respiratory failure and even death [1, 2, 6].

The pathogenic mechanism of SARS-CoV-2 is binding to membrane ACE2 for entering into pulmonary cells [4]. And ACE2 is widely distributing in several vital organs including lung, heart, kidney and intestine [7]. Apart from the respiratory symptom, SARS-CoV-2 also caused cardiovascular damage, not only led to acute cardiac injury (ACI) with an increased high-sensitivity cardiac troponin I (hs-cTnI) in clinic [1]. On the other hands, patients with pre-existing cardiovascular diseases (CVDs) are more likely developed into the severe condition and even contribute to highly mortality [1, 8, 9]. Moreover, SARS-CoV-2 has an impact on the gastrointestinal system, bringing symptom like diarrhea with a statistically significant difference, which may be underestimated on clinical diagnosis [10]. Further study has proved that SARS-CoV-2 infects the gastrointestinal tract, the results of histologic and immunofluorescent staining of gastrointestinal tissues from COVID-19 patients were showed that the existence of ACE2 receptor and viral nucleocapsid protein in the cytoplasm of gastric, duodenal, and rectum glandular epithelial cell [11].

Therefore, we are also concerned whether SARS-CoV-2 causes kidney dysfunction and whether COVID-19 patients with kidney impairment are at a higher risk. Some clinical studies have focus attention on kidney injury of COVID-19 patients. Zhen Li et al. has shown that a large proportion of COVID-19 patients is accompanied by kidney dysfunction, including proteinuria, hematuria, increased serum creatine and blood urea nitrogen [12]. Yichun Cheng also demonstrated that kidney injury is associated with in-hospital death of COVID-19 patients [13]. However, Luwen Wang thought that SARS-CoV-2 did not cause obviously kidney damage to patients [14]. With issue arising, a meta-analysis with large clinical samples is desperately warranted to produce a convincible result.

Methods

Our study was conducted following Preferred Reporting Items for Systematic Reviews and Meta-Analyses of individual participant data (the PRISMA-IPD) statement [15].

Data source, search strategy and selection criteria

PubMed, EMBASE, and MedRxiv databases were applied for searching studies published from December 2019 to May 2020. To identify all the articles displaying the renal injury and impairment in COVID -19, we used the following keywords or search terms alone and in combination: “novel coronavirus”, “China”, “HCoV”, “nCoV” “Wuhan”, “COVID-19” “SARS-CoV-2”, “clinical”, “laboratory”, “kidney”, “Acute Kidney Injury”, “proteinuria” and “hematuria”. Detailed search strategies were illustrated in .

Two reviewers (Q.Y. & X.Y.) independently screened the titles, abstracts and followed the full texts to decided which studies should be included in. Inclusion criteria are as follows:(1) comparative studies: randomized controlled trials RCTs or non-RCTs published only restricted in English; (2) patients in the studies should be confirmed to have been infected by COVID-19; (3)studies containing information about the clinical or laboratory characteristics (4) studies containing the comorbidities of kidney dysfunction and the outcome of kidney impairment. Exclusion criteria are (1) studies that less than 10 patients were included; (2) case reports, editorials, comments, non-clinical studies, reviews, studies without reliable information; (3) studies with special populations (e.g., only focused on children or severe or death cases).

Data extraction and study quality assessment

Prevalence of comorbidities and clinical manifestations of kidney damage, including AKI, proteinuria and hematuria, together with laboratory indexes of kidney impairment (confirmed by elevation of Scr, BUN and D-dimer) were extracted from the identified studies. The subgroup measure parameters were to compare the incidences of AKI and the mean differences of the three laboratory indicators among ICU and Non-ICU cases (severe and non-severe data as the second choice if ICU data was not provided). Cochrane Collaboration’s tool was applied to evaluate the risk of bias.

Statistical analysis

All analyses were performed using OpenMeta Analyst (version 12.11.14) (http://www.cebm.brown.edu/openmeta/) and Review Manager (version 5.3). Forest plots were used to depict the incidences of clinical and laboratory features of kidney dysfunction of COVID-19 patients. The odds ratio (OR, 95% confidence intervals (CI)) and mean differences (MD, 95% confidence intervals (CI)) were used to illustrate the comprehensive effects of COVID-19 occurring in ICU/severe patients and non-ICU/non-severe patients. And I2 statistics were used to assess the statistical heterogeneity. The fixed-effect model was used if I2 < 50% and the random effect model was used if I2 ≥ 50% [8]. The funnel plots were used to show the risk of publication bias.

Results

Selected literature and studies characteristics

At initially, we have searched a total of 838 studies after 231 duplicate studies were identified. Following reviewed the titles and abstracts, we ruled out 772 non-clinical research, reviews, comments, case reports and studies of participants less than 10. With the remaining 66 documents, we reviewed and evaluated the whole articles with detailed information. We further excluded 47 records for multiple reasons such as lacking enough clinical information and only demonstrated the exceptional cases. In the result, we identified 24 eligible studies meeting our inclusion criteria for our meta-analysis, including 10180 COVID-19 positive patients (). All of them were retrospective, descriptive observational studies including 17 single-center and 7 multiple-center studies from different countries and regions, which were mainly conducted between December 2019 and May 2020.

The epidemiological and clinical characteristics of COVID-19 from 19 included studies were illustrated in . And we also described the prevalence of the complications of kidney injury on clinic and laboratory features. Among all selected studies, the infected men accounted for a more substantial proportion than women and the men to women ratio was 1.4. The mean age of the participants was 54.6 years (95% CI, 51.2–58.0).

AKI and biomarkers of kidney dysfunction

Our outcome of meta-analysis for identified studies suggested that the AKI occurred 16.2% (95% CI 7.0–25.3%) in COVID-19 patients (). According to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines [16] and the limited clinical and laboratory information acquired from those studies, we used several indicators to display the comorbidities of kidney dysfunction. And the most prevalent laboratory indexes were increased Scr (8.3%, 95% CI 4.3–12.3%) (), increased BUN (6.2%, 95% CI 2.4–10.1%) () and increased D-dimer (49.8%, 95% CI 35.4–64.2%) (). We included D-dimer for the reason that the elimination of D-dimer protein partially happens through kidney and high D-dimer is associated with the dysfunction of kidney [17]. However, the I2 index ranging from 82% to 99% revealed significant heterogeneity in the evaluation of AKI, Scr, BUN and D-dimer among the included studies (P<0.001) ().

Meta-analysis of incidences of AKI and three laboratory indexes of kidney injury.

Forest plots represent the comparisons of the prevalence of AKI and mean differences (MD) in three laboratory indicators between ICU/severe and non-ICU/non-severe cases. A, serum creatinine (Scr, μmol/L); B, blood urea nitrogen (BUN, μmol/L); C, D-dimer(mg/L).

Risk stratification factors for COVID-19

To identify the risk factors for critical illnesses of COVID-19 patients, we then analyzed the relevance of the AKI and the three laboratory indexes with the clinical severity through comparing the incidences of AKI and mean differences of those biomarkers between ICU/severe and non-ICU/non-severe cases. Following the results of the heterogeneity test were all shown as I2 <50%, we applied the fixed-effect model for further investigations. For AKI, the result from 9 studies including 7313 patients showed that the AKI occurred statistically significantly higher in ICU cases (73.2%) compared with non-ICU cases (16.5%) [OR 29.51 95%CI (24.45, 35.62), Z = 35.27, P<0.00001] (). In terms of laboratory results, there were considerable differences between ICU and non-ICU cases in Scr (MD = 6.38 μmol/L, 95%CI 3.10–9.65, 13 studies, n = 1267) (), BUN(MD = 1.84μmol/L, 95%CI 1.44–2.25, 7 studies, n = 701) () and D-dimer (MD = 0.67mg/L, 95%CI 0.54–0.79, 12 studies, n = 1553) (). In conclusion, AKI, increased Scr, BUN and D-dimer were prominent features when patients developed into critical conditions (all P<0.001) ().

Clinical characteristics of kidney impairment

AKI is a risk factor of proteinuria and subsequently can be developed into chronic kidney disease(CKD) [18]. Here, we sought to further explore the clinical effects of kidney impairment caused by COVID-19, and we analyzed another two clinical features among COVID-19 patients. The results show that the most prevalent of kidney injury comorbidities were proteinuria (50.1%, 95%CI 26.8%-73.4%) () and hematuria (30.3%, 95%CI 20.6%-40.1%) () with high heterogeneity (both I2> 80%).

Meta-analysis of incidences of two clinical characteristics of kidney injury.

A, proteinuria; B, hematuria.

Sensitivity analysis and bias assessment

In the end, the funnel plots displayed symmetrical distributions of the effect sizes of AKI, Scr, BUN and D-dimer, and presented no obvious publication bias ().

Funnel plots of the comparisons of AKI.

(A), Scr (B), BUN (C) and D-dimer (D) between ICU/severe and non-ICU/severe patients.

Discussion

The COVID-19 has affected hundreds of millions of people posing a huge healthy threaten and bring a major burden to public healthcare institutions around the world. Compared with the other two pathogenic coronaviruses family members SARS-CoV and MERS-CoV, SARS-CoV-2 is higher contagious causing global pandemic, whereas each of which has its own clinical manifestation. Studies have been reported that SARS-CoV-2 is sharing highly 79.6% genome sequence identity as well as high molecular structure similarity with SARS-CoV [4, 19]. Therefore, SARS-CoV-2 uses ACE2 as a cellular entry receptor as SARS-CoV [4, 20]. ACE2 is highly expressed in multiple systems and tissues, mainly in the respiratory, cardiovascular, renal and gastrointestinal systems [7]. In addition to respiratory diseases and cardiac damage caused by SARS-CoV-2 through ACE2, we still need to consider the possibility of kidney effects on COVID-19 patients.

The meta-analysis was based on data from 24 studies with confirmed 10180 COVID-19 cases in worldwide. In all cases, men were a more significant population around 58% than women, which has similar infection characteristics as MERS and SARS [21, 22]. Our meta-analysis has shown that the prevalence of AKI is approximately 16.2%, and other laboratory biomarkers reflecting renal injuries such as increased Scr, BUN and D-dimer were presented in 8.3%, 6.2%, 49.8%, respectively. Moreover, the clinical features of kidney dysfunction are even higher than cardiovascular diseases in COVID-19 patients, proteinuria is 50.1% and hematuria is 30.3%, while hypertension and diabetes were showed around 8% and 5% in Jing Yang’s study [9]. And other researchers have showed the similar results of the prevalence of increased Scr(9.6%), BUN(13.7%) and proteinuria(57.2%) in their meta analysis [23].

We have further analyzed the correlation ship between the COVID-19 and kidney dysfunction while other studies have not noted. When compared the ICU/severe and non-ICU/non-severe cases, our results demonstrated that the AKI happened 30-folds higher in critical condition, while the incidence of acute cardiac injury was around 13-folds higher in severe disease in Bo Li’s study [8]. Moreover, the indexes of Scr, BUN and D-dimer were demonstrated 6.4-folds, 1.8-folds and 0.67-folds, respectively, higher when patients developed into ICU/severe illness. At all, the AKI is highly associated with severe COVID-19 and more susceptibility than cardiac damage so that we should pay more attention to protecting the normal function and recovery of kidney in clinic.

However, there are still some limitations for this meta-analysis. Firstly, due to the restriction of clinic information from the literatures and most of the studies did not include in the death cases or the mortality of COVID-19, the association between kidney impairment and COVID-19-induced death was not be analyzed in our meta-analysis. And we hardly could include study compared the complications of kidney injury between ICU/severe and non-ICU/non-severe patients. In which cases, we did not perform sensitivity analysis and subgroup analysis for proteinuria, hematuria or uric acid. Secondly, we found that the high statistic heterogeneity in the prevalence of kidney injury analysis. The reasons are related to the study designs and significant variations among studies in the sample sizes. Thirdly, therapies under investigation for COVID-19 may have kidney side effects as lots of drugs are nephrotoxic such as aminoglycosides, ACE inhibitors and nonsteroidal anti-inflammatory drugs (NSAIDs), we are not sure whether some clinical data we got have such possibility involved, and we could not rule out the influences caused by drugs on kidney during the hospitalization.

In this meta-analysis, we have showed AKI is a critical bio-indicator for COVID-19 patients developed into severe condition. Other clinical researchers founded that black race was more susceptible to AKI [24]. Also, there are several risk factors were reported to have worse outcomes even higher mortality when infected with COVID-19, including increased age, higher BMI, smoking, male sex, African Americans and Hispanics ethnicity, and people with other comorbidities, especially cardiovascular diseases [25-28]. As a result, risk stratification, individualize interventions and early therapeutic measures are required for clinical management in order to prevent the progression of AKI and reduce mortality and morbidity.

Some mechanisms are involved for explanation of kidney injury during the COVID-19 infection episodes. Firstly, ACE-2 distributes on tubular epithelial cells of the kidney with a higher expression level compared to the lung. Thus, the kidney is also a direct aim organ attacked by SARS-CoV-2 entering into target cells through ACE-2 acting as the way in the lung. In most recently pathological autopsy results, researchers found that coronavirus-like particles were directly discovered in kidney through immunohistochemistry on patients died with COVID-19 and SARS-CoV nucleoprotein antibody were indirectly detected in kidney tissue by immunofluorescent staining on COVID-19 patients [29, 30]. All those evidences have been demonstrated that the infection of COVID-19 and immunodysregulation on kidney, which caused AKI in the early stage and significant comorbidities such as hypertension, chronic kidney disease in the long term [30]. Moreover, coronavirus-like particles also were detected in other critical organs including respiratory system and gastrointestinal tract, causing obstructive sleep apnoea, diabetes and obesity [30]. Therefore, we still need to follow-up the outcome of those COVID-19 patients in the future. And establishing the chronic diseases community will play a critical role in the management and treatment of patients affected by this epidemic disease.

Besides, the crosstalk relationship between lung and kidney. Kidney damage can be caused by circulating inflammatory factors such as tumor necrosis factor (TNF)-α and interleukin (IL)-6, which are originated from pneumonia, happened in the lung. Furthermore, the local inflammatory response from injury and death renal cells will accelerate damage in the development of AKI as well as other organs [31, 32]. Thus, to reduce the possibility of developing into critically illness and the mortality risk for COVID-19 patients, applying more protective measures and supportive medication interventions is necessary, which has a significant influence for the kidney care of patients, including the application of drugs with mild kidney adverse effects, renal replacement therapies (RRT) like blood filtering and purification treatments etc. For example, continuous RRT with continuous veno-venous haemo-dialysis modality (CVVHD) is an efficacious way to prevent the progression of severity in COVID-19 patients, especially those with refractory hypoxaemia and unstable haemodynamic status [33]. Also, the application of CVVHD is helpful to increase cytokine removal which mitigates the kidney damage induced by inflammatory factors [34]. Moreover, RRT coupled with low-flow extracorporeal carbon dioxide removal (ECCO2R) would be a better and supportive therapy for the critical illness, however, still need to be verification with sufficiently clinical trials [33].

On the other hand, we should analyze the reasons accounting for underestimating kidney impairment in COVID-19 patients in clinic. Firstly, the laboratory tests of blood chemistry analysis, including Scr and BUN, will only elevate into abnormal range when kidney lost at least 50% function because of the potent compensatory ability of kidney. From our results, we also found that the proportions of aberrant urinalysis were more than the percentage of increased plasma biomarkers. Secondly, the difficulty of precise diagnosis of AKI is another possible aspect responsible for the underrating of AKI. The detection rate of AKI mainly depends on the fluctuation of Scr and the frequency of Scr testing. And a higher incidence of AKI will be detected with adjusted denser Scr testing frequency. Therefore, more accurate strategies should be applied to the clinic when considered AKI [35]. There are several biomarkers can be used for monitoring the kidney function such as the level fluctuation of creatinine and urine output with the volume and hemodynamic status, and some novel indicators also should be added in for precisely stratifying the AKI severity such asTIMP-2 (tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor binding protein 7(IGFBP7) [36].

In conclusion, SARS-CoV-2 causes renal injury progressing to severe AKI. At the same time, AKI is a life-threatening complication associating with a severer condition in COVID-19 patients. Therefore, we should focus more attention to kidney damage at the early stage when patients are confirmed been infected by COVID-19 according to a series of accurate clinical parameters. And more protective therapies are urged to be confirmed the clinical value on COVID-19 patients with kidney dysfunction.

PRISMA 2009 checklist.

(DOC)

Click here for additional data file.

17 Sep 2020

PONE-D-20-15148

Incidence and risk factors of kidney impairment on patients with COVID-19: a systematic review and meta-analysis

PLOS ONE

Dear Dr. Yang,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Nov 01 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Chiara Lazzeri

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: 1. The studies included was limited in China.To get a more comprehensive understanding of kidney impairment on patients with COVID-19, more researches from different countries and regions will be better.

2. Recent study ( such as Crit Care. 2020 Jun 18;24(1):356,and probably more)  has reported the acute renal impairment on COVID-19.The manuscript should compare with  similar systematic reviews in discussion.

3. It is not mentioned whether more than one investigators work independently to decide which studies should be included.

Reviewer #2: This is a timely review paper on COVID and kidney disease. The authors start with 838 studies, down to 66 then 19. They then summarize the clinical characteristics of the patient with AKI, the incidence if in the ICU or out, and associated proteinuria and hematuria as risk factors.

Comments

1. The current study does not add to the current major questions about COVID and the kidney. What is going on in biopsies? What are the main comorbidities? Who will survive and who will not? What dialysis modalities are the best for those critically ill? How does organ dysfunction in other organs contribute?

2. There are many other key original papers on COVID and kidney disease that are not discussed and reflect very important clinical data

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

16 Oct 2020

Dear Editor Chiara Lazzeri,

Many thanks for proving us an opportunity for us to make further revisions for our manuscript titled “Incidence and risk factors of kidney impairment on patients with COVID-19: a systematic review and meta-analysis” submitted to Plos One. We appreciate the patience and efforts that you and the reviewers have worked on our paper, and more importantly, provided many thoughtful suggestions and valuable comments for our research study. We have been able to address most of the questions raised from the reviewers. We have made traceable changes and highlight the revisions in our manuscript.

Here is the point-by-point response to the reviewers’ comments and concerns.

Reviewer #1: 1. The studies included was limited in China. To get a more comprehensive understanding of kidney impairment on patients with COVID-19, more researches from different countries and regions will be better.

2. Recent study ( such as Crit Care. 2020 Jun 18;24(1):356,and probably more) has reported the acute renal impairment on COVID-19.The manuscript should compare with similar systematic reviews in discussion.

3. It is not mentioned whether more than one investigators work independently to decide which studies should be included.

Response: Thank you so much for the first crucial point that we need to include more studies rather than just narrowed in China. Therefore, we have added in more 5 studies from other countries, and accordingly, we have made revisions on our results which can be found in abstract part(page2), result part(page 6-8), and in table1, Figure 1-4[1][2][3][4][5]:

In the sum of 24 studies with 10180 patients were included in this analysis. The pooled prevalence of AKI, increased serum creatinine (Scr), increased blood urea nitrogen (BUN), increased D-dimer, proteinuria and hematuria in patients with COVID-19 were 16.2%, 8.3%, 6.2%, 49.8%, 50.1% and 30.3% respectively. Moreover, the means of Scr, BUN and D-dimer were shown 6.4-folds, 1.8-folds and 0.67-folds, respectively, higher in ICU/severe cases than in corresponding non-ICU/non-severe patients. The prevalence of AKI was about 30 folds higher in ICU/severe patients compared with the non-ICU/non-severe cases.

For the secondly point, we also have made comparisons with other similar meta-analysis, such as Xianghong Yang et al. have reported the similar results of the prevalence of increased Scr(9.6%), BUN(13.7%) and proteinuria(57.2%) in their meta-analysis, which can be found in discussion part(page 9).

For the third point, thanks for reminding us to make more clear statement in our method. We have noted that two reviewers (Q.Y. & X.Y.) independently screened the titles, abstracts and followed the full texts to decided which studies should be included in, which can be found in method part (page 5).

Reviewer #2: This is a timely review paper on COVID and kidney disease. The authors start with 838 studies, down to 66 then 19. They then summarize the clinical characteristics of the patient with AKI, the incidence if in the ICU or out, and associated proteinuria and hematuria as risk factors.

Comments

1. The current study does not add to the current major questions about COVID and the kidney. What is going on in biopsies? What are the main comorbidities? Who will survive and who will not? What dialysis modalities are the best for those critically ill? How does organ dysfunction in other organs contribute?

2. There are many other key original papers on COVID and kidney disease that are not discussed and reflect very important clinical data

Response: Appreciate for those insightful questions that will make our paper, especially discussion part, more comprehensive and significant. Here we will answer the questions point by point:

What is going on in biopsies? What are the main comorbidities?

Answer can be found in discussion part(page11): In most recently pathological autopsy results, researchers found that coronavirus-like particles were directly discovered in kidney through immunohistochemistry on patients died with COVID-19 and SARS-CoV nucleoprotein antibody were indirectly detected in kidney tissue by immunofluorescent staining on COVID-19 patients[6][7]. All those evidences have been demonstrated that the infection of COVID-19 and immunodysregulation on kidney, which caused AKI in the early stage and significant comorbidities such as hypertension, chronic kidney disease in the long term[7]. Moreover, coronavirus-like particles also were detected in other critical organs including respiratory system and gastrointestinal tract, causing obstructive sleep apnoea, diabetes and obesity[7].

How does organ dysfunction in other organs contribute?

Answer can be found in discussion part(page12): Firstly, coronavirus-like particles also were detected in other critical organs including respiratory system and gastrointestinal tract, causing obstructive sleep apnoea, diabetes and obesity, which means other organs could be attacked by virus directly [7]. Also, the crosstalk relationship between lung and kidney. Kidney damage can be caused by circulating inflammatory factors such as tumor necrosis factor (TNF)-α and interleukin (IL)-6, which are originated from pneumonia, happened in the lung. Furthermore, the local inflammatory response from injury and death renal cells will accelerate damage in the development of AKI as well as other organs[8][9].

Who will survive and who will not?

Answer can be found in discussion part(page10-11): In this meta-analysis, we have showed AKI is a critical bio-indicator for COVID-19 patients developed into severe condition. Other clinical researchers founded that black race was more susceptible to AKI[5]. Also, there are several risk factors were reported to have worse outcomes even higher mortality when infected with COVID-19, including increased age, higher BMI, smoking, male sex, African Americans and Hispanics ethnicity, and people with other comorbidities, especially cardiovascular diseases[10][11][12][13]. As a result, risk stratification, individualize interventions and early therapeutic measures are required for clinical management in order to prevent the progression of AKI and reduce mortality and morbidity.

What dialysis modalities are the best for those critically ill?

Answer can be found in discussion part(page12): To reduce the possibility of developing into critically illness and the mortality risk for COVID-19 patients, applying more protective measures and supportive medication interventions is necessary, which has a significant influence for the kidney care of patients, including the application of drugs with mild kidney adverse effects, renal replacement therapies (RRT) like blood filtering and purification treatments etc. For example, continuous RRT with continuous veno-venous haemo-dialysis modality (CVVHD) is an efficacious way to prevent the progression of severity in COVID-19 patients, especially those with refractory hypoxaemia and unstable haemodynamic status[14]. Also, the application of CVVHD is helpful to increase cytokine removal which mitigates the kidney damage induced by inflammatory factors[15]. Moreover, RRT coupled with low-flow extracorporeal carbon dioxide removal (ECCO2R) would be a better and supportive therapy for the critical illness, however, still need to be verification with sufficiently clinical trials[14].

There are many other key original papers on COVID and kidney disease that are not discussed and reflect very important clinical data

Many thanks for your thought-provoking point. To address this problem, we have included in more 5 studies from other countries including the original clinic paper especially about the kidney injury and COVID-19, and accordingly, we have made revision on our results which can be found in abstract party(page2), result part(page 6-8), and in table1, Figure 1-4[1][2][3][4][5]:

In the sum of 24 studies with 10180 patients were included in this analysis. The pooled prevalence of AKI, increased serum creatinine (Scr), increased blood urea nitrogen (BUN), increased D-dimer, proteinuria and hematuria in patients with COVID-19 were 16.2%, 8.3%, 6.2%, 49.8%, 50.1% and 30.3% respectively. Moreover, the means of Scr, BUN and D-dimer were shown 6.4-folds, 1.8-folds and 0.67-folds, respectively, higher in ICU/severe cases than in corresponding non-ICU/non-severe patients. The prevalence of AKI was about 30 folds higher in ICU/severe patients compared with the non-ICU/non-severe cases.

Additional clarifications:

In addition to respond the above comments, all spelling and grammatical errors have been double checked again and corrected.

We look forward to hearing any feedback from you about our new submission and to respond any further questions and comments you may have.

Thanks again for your patience.

Sincerely,

Qixin Yang, Xiyao Yang

10/16/2020

Reference

1. Aggarwal S, Garcia-Telles N, Aggarwal G, Lavie C, Lippi G, Henry BM. Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States. Diagnosis. 2020;7: 91–96. doi:10.1515/dx-2020-0046

2. Antinori S, Cossu MV, Ridolfo AL, Rech R, Bonazzetti C, Pagani G, et al. Compassionate remdesivir treatment of severe Covid-19 pneumonia in intensive care unit (ICU) and Non-ICU patients: Clinical outcome and differences in post-treatment hospitalisation status. Pharmacological Research. 2020;158: 104899. doi:10.1016/j.phrs.2020.104899

3. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. The Lancet. 2020;395: 1763–1770. doi:10.1016/S0140-6736(20)31189-2

4. Arentz M, Yim E, Klaff L, Lokhandwala S, Riedo FX, Chong M, et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020;323: 1612. doi:10.1001/jama.2020.4326

5. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney International. 2020;98: 209–218. doi:10.1016/j.kint.2020.05.006

6. Su H, Yang M, Wan C, Yi L-X, Tang F, Zhu H-Y, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney International. 2020;98: 219–227. doi:10.1016/j.kint.2020.04.003

7. Bradley BT, Maioli H, Johnston R, Chaudhry I, Fink SL, Xu H, et al. Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series. The Lancet. 2020;396: 320–332. doi:10.1016/S0140-6736(20)31305-2

8. Joannidis M, Forni LG, Klein SJ, Honore PM, Kashani K, Ostermann M, et al. Lung–kidney interactions in critically ill patients: consensus report of the Acute Disease Quality Initiative (ADQI) 21 Workgroup. Intensive Care Med. 2020;46: 654–672. doi:10.1007/s00134-019-05869-7

9. Teixeira JP, Ambruso S, Griffin BR, Faubel S. Pulmonary Consequences of Acute Kidney Injury. Semin Nephrol. 2019;39: 3–16. doi:10.1016/j.semnephrol.2018.10.001

10. Zhang J, Dong X, Cao Y, Yuan Y, Yang Y, Yan Y, et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China. Allergy. 2020; all.14238. doi:10.1111/all.14238

11. Simonnet A, Chetboun M, Poissy J, Raverdy V, Noulette J, Duhamel A, et al. High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) Requiring Invasive Mechanical Ventilation. Obesity. 2020;28: 1195–1199. doi:10.1002/oby.22831

12. Jordan RE, Adab P, Cheng KK. Covid-19: risk factors for severe disease and death. BMJ. 2020; m1198. doi:10.1136/bmj.m1198

13. Johns Hopkins Coronavirus Resource Center. Racial data transparency: states that have released breakdowns of Covid-19 data by race. https://coronavirus.jhu.edu/data/racial-data-transparency.

14. Ronco C, Reis T, Husain-Syed F. Management of acute kidney injury in patients with COVID-19. The Lancet Respiratory Medicine. 2020;8: 738–742. doi:10.1016/S2213-2600(20)30229-0

15. Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat Rev Nephrol. 2020;16: 308–310. doi:10.1038/s41581-020-0284-7

Submitted filename: Response to reviewers.docx

Click here for additional data file.

26 Oct 2020

Incidence and risk factors of kidney impairment on patients with COVID-19: a systematic review and meta-analysis

PONE-D-20-15148R1

Dear Dr. Yang,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Chiara Lazzeri

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

5 Nov 2020

PONE-D-20-15148R1

Incidence and risk factors of kidney impairment on patients with COVID-19: a systematic review and meta-analysis

Dear Dr. Yang:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Chiara Lazzeri

Academic Editor

PLOS ONE

Table 1

Study characteristics including number, location, age, sex and kidney impairment of patients of the 24 included studies.

Studies	Study period	Number of patients	location	Mean age (SD)	Sex (male,%)	Kidney metabolic diseases
						AKI %	Increased Scr %	Increased BUN %	Increased D-dimer %	Proteinuria %	Hematuria %
Zhen Li et al. [12]	1/6/2020-2/21/2020	193	Wuhan, Huangshi, Chongqing	56.7(15.6)	95(49%)	28.5	10.4	14.0	58.8	58.9	44.2
Yichun Cheng et al. [13]	1/28/2020-2/11/2020	710	Wuhan	61.7(14.8)	374(52.7%)	3.2	15.5	-	77.7	44.0	26.9
Haifeng Zhou et al. [37]	2/2/2020-2/29/2020	178	Wuhan	47.7(19.3)	72 (40.4%)	-	0.0	2.8	-	34.9	28.9
Fei Zhou et al. [38]	12/29/2019-1/31/2020	191	Wuhan	56.3(15.6)	119(62%)	14.7	4.3	-	68.0	-	-
Nanshan Chen et al. [6]	1/1/2020-1/20/2020	99	Wuhan	55.5(13.1)	67(68%)	3.0	-	6.1	36.4	-	-
Chaolin Huang et al. [1]	12/16/2019-1/2/2020	41	Wuhan	49.3(12.6)	30(73%)	7.3	9.8	-	-	-	-
Qingxian Cai et al. [39]	1/11/2020-2/6/2020	298	Shenzhen	47.0(20.7)	149(50%)	5.7	4.4	4.0	35.7	-	-
Weijie Guan et al. [40]	12/11/2019-1/29/2020	1099	Nationwide	46.7(17.0)	637(58%)	0.5	1.6	-	46.4	-
Dawei Wang et al. [2]	1/1/2020-1/28/2020	138	Wuhan	55.3(19.3)	75(54.3%)	3.6	-	-	-	-	-
Jiatao Lu et al. [41]	1/21/2020-2/5/2020	577	Wuhan	53.3(20)	254(44%)	-	3.0	-	33.5	-	-
Jinjin Zhang et al. [25]	1/16/2020-2/3/2020	140	Wuhan	57.2(14.8)	71(50.7%)	-	-	-	43.2	-	-
Weihe Quan et al. [42]	2/25/2020-3/13/2020	18	Shenzhen, Wuhan	60.3(15.3)	NA	-	-	-	-	22.2	16.7
Yonghao Xu et al. [43]	2/28/2020	45	Guangdong	56.7(15.4)	29(64.4%)	15.6	-	-	-	-	-
Guang Chen et al. [44]	12/19/2019-1/27/2020	21	Wuhan	57.0(11.1)	17(81%)	-	-	-	-	-	-
Yanli Liu et al. [45]	1/2/2020-2/1/2020	109	Wuhan	54.7(17.0)	59(54.1%)	-	-	-	-	-	-
Jingyuan Liu et al. [46]	1/13/2020-1/31/2020	61	Beijing	42.3(15.7)	31(50.8%)	-	-	-	-	-	-
Lei Liu et al. [47]	1/11/2020-2/6/2020	51	Chongqing	43.3(12.6)	32(63%)	-	-	-	-	-	-
Zhichao Feng et al. [48]	1/17/2020-2/1/2020	141	Hunan	44.3(15.3)	72(51.1%)	-	-	-	-	-	-
Hongzhou Lu et al. [49]	1/20/20-2/19/2020	265	Shanghai	NA	NA	-	-	-	-	-	-
Saurabh Aggarwal et al. [50]	3/1/2020-4/4/2020	43	Jersey, USA	66.7(42.2)	32(74.4%)	68.8	68.8	-	-	-	-
Spinello Antinori et al. [51]	2/23/2020-3/20/2020	35	Italy	61.0(13.3)	26(74.3%)	22.8	-	-	-	-	-
Matthew J Cummings et al. [52]	3/2/2020-4/1/2020	257	New York, USA	61.7(15.6)	171(66.5%)	-	-	-	-	0.9	-
Matt Arentz et al. [53]	NA	21	Seattle, USA	68.3(36.3)	11(52.4%)	19.1	-	-	-	-	-
Jamie S. Hirsch et al. [24]	3/1/2020-4/5/2020	5449	New York, USA	63.7(17.0)	3317(60.9%)	36.6	-	-	-	-	-

AKI, acute kidney injury; Scr serum creatinine; BUN blood urea nitrogen.